Humpath.com - Human pathology

Home > A. Molecular pathology > Targeted therapy > Small molecules > cabozantinib

cabozantinib

Saturday 15 October 2016

Notes

- Cabozantinib improves ORR (46% vs 18%) & PFS (8.2 vs 5.6 months) compared with sunitinib in untreated intermediate/high-risk mRCC